A5107051684- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Ovarian cancer diagnosis and treatment
- Gallbladder and Bile Duct Disorders
- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- BRCA gene mutations in cancer
- HER2/EGFR in Cancer Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Pediatric Hepatobiliary Diseases and Treatments
- Esophageal Cancer Research and Treatment
- Colorectal and Anal Carcinomas
- Genetic factors in colorectal cancer
- Endometrial and Cervical Cancer Treatments
- Breast Implant and Reconstruction
- Renal and related cancers
- Immune cells in cancer
- Colorectal Cancer Surgical Treatments
- Radiomics and Machine Learning in Medical Imaging
- Gastric Cancer Management and Outcomes
University of Amsterdam
2016-2024
Amsterdam University Medical Centers
2019-2024
Cancer Center Amsterdam
2018-2022
Amsterdam UMC Location University of Amsterdam
2016-2018
Amsterdam UMC Location Vrije Universiteit Amsterdam
2018
Abstract Immune checkpoint inhibition (ICI) has fundamentally changed cancer treatment. However, only a minority of patients with metastatic triple negative breast (TNBC) benefit from ICI, and the determinants response remain largely unknown. To better understand factors influencing patient outcome, we assembled longitudinal cohort tissue multiple timepoints, including primary tumor, pre-treatment on-treatment tumor 117 treated ICI (nivolumab) in phase II TONIC trial. We used highly...
The recently identified classical and basal-like molecular subtypes of pancreatic cancer impact on overall survival (OS). However, the added value routine subtyping in both clinical practice randomized trials is still unclear, as most studies do not consider clinicopathological parameters. This study examined prognostic patients with resected cancer.Subtypes were determined fresh-frozen samples from three Dutch centres using Purity Independent Subtyping Tumours classification. Patient,...
Ovarian cancer has the worst overall survival rate of all gynecologic malignancies. For majority patients, 5-year less than 50% hardly improved over last decades. To improve outcome patients with subtypes ovarian cancer, large-scale fundamental and translational research is needed. accommodate these types research, we have established a Dutch nationwide, interdisciplinary infrastructure biobank: Archipelago Cancer Research (AOCR). The AOCR will facilitate enhance interdisciplinary, national,...
Fundamental and translational research in ovarian cancer aims to enhance understanding of disease mechanisms improve treatment survival outcomes. To support this, we established the Dutch multicenter, interdisciplinary Archipelago Ovarian Cancer Research (AOCR) infrastructure, which includes a nationwide biobank. In this study, share our experiences establishing offer guidance for similar initiatives, evaluate AOCR patient cohort. Key challenges included obtaining Data Protection Impact...
TPS4142 Background: Despite multimodality treatment the outcome of esophageal adenocarcinoma (EAC) is poor. In EAC, human epidermal growth factor receptor 2 (HER2) overexpressed in 19% to 43% cases. Based on positive results ToGA trial metastatic esophagogastric cancer, HER2 targeting currently investigated patients treated with curative intent. Most patients, however, develop resistance trastuzumab. Recent studies breast cancer evaluating effect combined HER2/HER3 trastuzumab and pertuzumab...